Published in Blood Weekly, December 31st, 2009
Myelofibrosis is a serious disorder that disrupts the body's normal production of blood cells. The result is extensive scarring in the bone marrow, leading to severe anemia, weakness, fatigue and often, an enlarged spleen and liver.
"In the past 20 years, management of primary myelofibrosis has incorporated new treatment approaches, but survival benefits for patients have not been confirmed," says Ayalew...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2009-12-31)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.